Symphogen's ITP therapy clears Phase II
This article was originally published in Scrip
The Danish biotech company Symphogen's rozrolimupab (SYM001) may be a useful alternative to plasma-derived products in the treatment of primary immune thrombocytopenia purpura (ITP), say researchers following a Phase II trial published in Blood.
You may also be interested in...
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the conference taking place in its condensed three-day format for just the second time. Scrip takes a look at the expected highlights.
Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.